SenicapocGardos channel and RBC inhibitor CAS# 289656-45-7 |
- THZ1
Catalog No.:BCC4005
CAS No.:1604810-83-4
- SNS-032 (BMS-387032)
Catalog No.:BCC1152
CAS No.:345627-80-7
- AZD-5438
Catalog No.:BCC3689
CAS No.:602306-29-6
- Dinaciclib (SCH727965)
Catalog No.:BCC3765
CAS No.:779353-01-4
- PD 0332991 (Palbociclib) HCl
Catalog No.:BCC3680
CAS No.:827022-32-2
- Palbociclib (PD0332991) Isethionate
Catalog No.:BCC3698
CAS No.:827022-33-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 289656-45-7 | SDF | Download SDF |
| PubChem ID | 216327 | Appearance | Powder |
| Formula | C20H15F2NO | M.Wt | 323.35 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | ICA-17043 | ||
| Solubility | DMSO : 50 mg/mL (154.64 mM; Need ultrasonic) | ||
| Chemical Name | 2,2-bis(4-fluorophenyl)-2-phenylacetamide | ||
| SMILES | C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N | ||
| Standard InChIKey | SCTZUZTYRMOMKT-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C20H15F2NO/c21-17-10-6-15(7-11-17)20(19(23)24,14-4-2-1-3-5-14)16-8-12-18(22)13-9-16/h1-13H,(H2,23,24) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Senicapoc is a potent and selective Gardos channel blocker with IC50 value of 11 nM, and blocks Ca2+-induced rubidium flux from human RBCs with an IC50 value of 11 nM and inhibits RBC dehydration with IC50 of 30 nM.In Vitro:ICA-17043 is shown to block the Gardos channel of mouse (C57 Black) RBCs with an IC50 of 50±6 nM. ICA-17043 blocks this increase in cellular hemoglobin concentration in human RBCs in a concentration-dependent fashion[1].In Vivo:ICA-17043 (10 mg/kg, p.o.) administration produces a significant decrease in Gardos channel activity measured at day 11 and 21 and is associated with a corresponding increase in red cell K+ content without changes in Na+ content. ICA-17043 (10 mg/kg, twice a day) induces a significant increase in Hct after 11 days of dosing in the SAD mouse[1]. Senicapoc (30 mg/kg, p.o.) reduces airway hyperresponsiveness, eosinophil numbers in bronchoalveolar lavage taken 48 hours post-allergen challenge, and vascular remodelling in the sheep[2]. References: | |||||
Senicapoc Dilution Calculator
Senicapoc Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.0926 mL | 15.4631 mL | 30.9262 mL | 61.8525 mL | 77.3156 mL |
| 5 mM | 0.6185 mL | 3.0926 mL | 6.1852 mL | 12.3705 mL | 15.4631 mL |
| 10 mM | 0.3093 mL | 1.5463 mL | 3.0926 mL | 6.1852 mL | 7.7316 mL |
| 50 mM | 0.0619 mL | 0.3093 mL | 0.6185 mL | 1.237 mL | 1.5463 mL |
| 100 mM | 0.0309 mL | 0.1546 mL | 0.3093 mL | 0.6185 mL | 0.7732 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Senicapoc is a potent inhibitor of the Gardos channel and ameliorates RBC dehydration in the SAD mouse. Senicapoc blocked Ca2+-induced rubidium flux from human RBCs with an IC50 value of 11 ± 2 nM (CLT IC50 = 100 ± 12 nM) and inhibited RBC dehydration with an IC50 of 30 ± 20 nM. Senicapoc is in treatment of Sickle Cell Disease and Sickle Cell Anemia
- Lasiodin
Catalog No.:BCN3387
CAS No.:28957-08-6
- Oridonin
Catalog No.:BCN5953
CAS No.:28957-04-2
- Cassiachromone
Catalog No.:BCN5192
CAS No.:28955-30-8
- Allo-Thr-OH
Catalog No.:BCC3101
CAS No.:28954-12-3
- Canertinib dihydrochloride
Catalog No.:BCC1449
CAS No.:289499-45-2
- Anodendrine
Catalog No.:BCN1956
CAS No.:28942-07-6
- Fmoc-Cl
Catalog No.:BCC2802
CAS No.:28920-43-6
- Triazolam
Catalog No.:BCC5218
CAS No.:28911-01-5
- 3,7,16-Trihydroxystigmast-5-ene
Catalog No.:BCN5191
CAS No.:289056-24-2
- Ergosta-5,24(28)-diene-3,7,16-triol
Catalog No.:BCN5190
CAS No.:289054-34-8
- Z-D-Met-OH
Catalog No.:BCC2758
CAS No.:28862-80-8
- S-(-)-Carbidopa
Catalog No.:BCN8453
CAS No.:28860-95-9
- Boc-HomoArg(NO2)-OH
Catalog No.:BCC2646
CAS No.:28968-64-1
- CB 300919
Catalog No.:BCC1456
CAS No.:289715-28-2
- Pectolinarin
Catalog No.:BCN1217
CAS No.:28978-02-1
- Persicoside
Catalog No.:BCN4780
CAS No.:28978-03-2
- Z-N-Me-Phe-OH
Catalog No.:BCC3349
CAS No.:2899-07-2
- H-Trp-Oet.HCl
Catalog No.:BCC2673
CAS No.:2899-28-7
- H-Tryptophanol
Catalog No.:BCC2701
CAS No.:2899-29-8
- H-Methioninol
Catalog No.:BCC2721
CAS No.:2899-37-8
- 3-(Benzylthio)-Propionic acid
Catalog No.:BCC2839
CAS No.:2899-66-3
- TRAM-34
Catalog No.:BCC1122
CAS No.:289905-88-0
- Boc-Phg-OH
Catalog No.:BCC3311
CAS No.:2900-27-8
- Methyl reserpate
Catalog No.:BCN3489
CAS No.:2901-66-8
Senicapoc: Repurposing a Drug to Target Microglia KCa3.1 in Stroke.[Pubmed:28364331]
Neurochem Res. 2017 Sep;42(9):2639-2645.
Stroke is the leading cause of serious long-term disability and the fifth leading cause of death in the United States. Treatment options for stroke are few in number and limited in efficacy. Neuroinflammation mediated by microglia and infiltrating peripheral immune cells is a major component of stroke pathophysiology. Interfering with the inflammation cascade after stroke holds the promise to modulate stroke outcome. The calcium activated potassium channel KCa3.1 is expressed selectively in the injured CNS by microglia. KCa3.1 function has been implicated in pro-inflammatory activation of microglia and there is recent literature suggesting that this channel is important in the pathophysiology of ischemia/reperfusion (stroke) related brain injury. Here we describe the potential of repurposing Senicapoc, a KCa3.1 inhibitor, to intervene in the inflammation cascade that follows ischemia/reperfusion.
Inhibition of the potassium channel KCa3.1 by senicapoc reverses tactile allodynia in rats with peripheral nerve injury.[Pubmed:27876619]
Eur J Pharmacol. 2017 Jan 15;795:1-7.
Neuropathic pain is a debilitating, chronic condition with a significant unmet need for effective treatment options. Recent studies have demonstrated that in addition to neurons, non-neuronal cells such as microglia contribute to the initiation and maintenance of allodynia in rodent models of neuropathic pain. The Ca(2+)- activated K(+) channel, KCa3.1 is critical for the activation of immune cells, including the CNS-resident microglia. In order to evaluate the role of KCa3.1 in the maintenance of mechanical allodynia following peripheral nerve injury, we used Senicapoc, a stable and highly potent KCa3.1 inhibitor. In primary cultured microglia, Senicapoc inhibited microglial nitric oxide and IL-1beta release. In vivo, Senicapoc showed high CNS penetrance and when administered to rats with peripheral nerve injury, it significantly reversed tactile allodynia similar to the standard of care, gabapentin. In contrast to gabapentin, Senicapoc achieved efficacy without any overt impact on locomotor activity. Together, the data demonstrate that the KCa3.1 inhibitor Senicapoc is effective at reducing mechanical hypersensitivity in a rodent model of peripheral nerve injury.
